Shares of NeuroSense Therapeutics shifted sharply higher on July 24, climbing 10.5% to $0.72, after the company announced it will file for Canadian approval of its lead ALS therapy following a productive meeting with Health Canada. For a company valued at roughly $25 million with zero revenue, the question isn't whether the science is promising — it's whether the business can survive long enough to capitalize.
• A Nearly 15-Month Survival Benefit Is a Big Deal for an Incurable Disease
NeuroSense's mid-stage trial showed a 14.9-month median survival benefit with a hazard ratio of 0.35 (p=0.0037), and the drug hit its primary biomarker endpoint (p=0.0421). ALS is a death sentence — an incurable disease that causes complete paralysis and death within 2–5 years from diagnosis. That context makes even Phase 2b survival data unusually compelling. The last ALS drug Canada approved conditionally — Albrioza — was later pulled from market after a larger trial failed to confirm benefit. NeuroSense's stronger survival signal could give regulators more comfort this time.
• Canada Is a Smaller Market, But It's a Strategic Beachhead
The Canadian ALS drug market is estimated at $100 million to $150 million annually , meaningful for a nano-cap company. NeuroSense expects to complete and file its New Drug Submission in the coming months. Canada has historically been willing to approve ALS treatments ahead of the FDA, making it a logical first market. A Canadian green light would generate early revenue and validate the drug for larger regulatory pursuits.
• The Company Has Almost No Cash Cushion
NeuroSense's current ratio — a basic measure of its ability to pay near-term bills — stands at just 0.31 , meaning it has far less cash on hand than it owes. With 35.35 million shares outstanding and the stock under a dollar, any commercialization effort will almost certainly require dilutive fundraising. Shares have traded between $0.58 and $2.10 over the past year , underscoring extreme volatility.
• The Drug Itself Is Surprisingly Simple — and That's a Double-Edged Sword
PrimeC is an oral pill combining two already-approved generic drugs: ciprofloxacin (an antibiotic) and celecoxib (an anti-inflammatory). That means manufacturing is cheap and scalable — NeuroSense has already completed commercial-scale manufacturing. But it also means the drug could be relatively easy to replicate, raising questions about long-term pricing power. Investors are buying regulatory momentum today; what they're really betting on is whether this tiny company can turn a clever drug combination into a viable business before running out of money.